In 2024, three different groups published several examples of 5-aminothalidomide-based PROTACs targeting Fms-like protein tyrosine receptor kinase 3 (FLT3), an established target in acute myeloid leukemia (AML)103. The gene discussed is FLT3; the disease is acute myeloid leukemia.